All blog posts
Showing 24 out of 93 results
31 七月 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
22 七月 2025
Overview of EU regulatory and competition law in the Pharma sector
13 五月 2025
EU Regulatory Reform for Medicinal Products: Changes to MAs, supply, and transparency
30 四月 2025
Reforms to the EU Regulatory framework for medicinal products
30 四月 2025
EU Regulatory Reform for Medicinal Products: Review of new regulatory exclusivities
18 三月 2025
Navigating competition law and FDI regulation in the pharmaceuticals sector - 2025 Outlook
10 二月 2025
Key Takeaways from the UPC Litigation Forum and Pharma & Biotech Patent Litigation Europe Summit 2025
30 一月 2025
The UPC at 18 months
29 一月 2025
Could we…and would we..? UK CoA confirms that it is bound by previous precedent on second medical use SPCs
29 一月 2025
Transparency at the UPC – accessing information, pleadings and evidence
19 十一月 2024
Sustainability - trends and developments life sciences companies should be aware of
01 十一月 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
Showing 24 out of 93 results
View moreKey contacts
Laura Orlando
Managing Partner, Milan Office, Milan
Alan Montgomery
Partner, Head of Life Sciences Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Life Sciences Sector, London